Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clobetasol propionate cream vs oral prednisone Disease control (healing of skin lesions) at day 21 · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 1.08 [1.03, 1.13] | 1 study · 341 participants | Moderate |
Doxycycline vs prednisolone Treatment‐related mortality at 1 year (mITT) · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.25 [0.07, 0.89] | 1 study · 234 participants | Moderate |
Doxycycline vs prednisolone Quality of life (DLQI) adjusted for baseline DLQI, disease severity, age, Karnovsky score, baseline versus week 52. A lower score is more favourable. · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | 1 study · 234 participants | High |
Doxycycline vs prednisolone Number of participants with grade 3‐4 (severe or life‐threatening) treatment‐related adverse events at 1 year (raw data) · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.59 [0.35, 0.99] | 1 study · 234 participants | Moderate |
Prednisone plus azathioprine vs prednisone Disease control (at 6 months) · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.93 [0.52, 1.66] | 1 study · 67 participants | Very low |
Prednisone plus azathioprine vs prednisone Mortality (at 6 months) · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 1.03 [0.35, 3.06] | 1 study · 67 participants | Very low |
Prednisone plus azathioprine vs prednisone Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Prednisone plus azathioprine vs prednisone Adverse events · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | Very low |
Nicotinamide plus tetracycline vs prednisone Disease control: complete response at 8 weeks: excluding dropouts · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 2.5 [0.37, 16.89] | 1 study · 18 participants | Very low |
Nicotinamide plus tetracycline vs prednisone Mortality at 6 months · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.18 [0.01, 3.85] | 1 study · 18 participants | Very low |
Nicotinamide plus tetracycline vs prednisone Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Clobetasol propionate cream vs oral prednisone Mortality at 1 year · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.73 [0.53, 1.01] | 1 study · 341 participants | Low |
Nicotinamide plus tetracycline vs prednisone Adverse events at 1 year · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | Very low |
Methylprednisolone plus azathioprine vs methylprednisolone plus dapsone Disease control (time when steroid could be discontinued) · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | 1 study · 54 participants | Very low |
Methylprednisolone plus azathioprine vs methylprednisolone plus dapsone Mortality at 1 year · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.33 [0.04, 3.01] | 1 study · 54 participants | Very low |
Methylprednisolone plus azathioprine vs methylprednisolone plus dapsone Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylprednisolone plus azathioprine vs methylprednisolone plus dapsone Adverse events at 1 year · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | Very low |
Clobetasol propionate cream vs oral prednisone Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Clobetasol propionate cream vs oral prednisone Adverse events: severe complications at day 21 · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.65 [0.5, 0.86] | 1 study · 341 participants | Low |
Mild clobetasol propionate cream regimen (10 to 30 g/day) vs standard clobetasol propionate cream regimen (40 g/day) Disease control (healing of skin lesions) at day 21. Intention‐to‐treat analysis, all participants · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 1 [0.97, 1.03] | 1 study · 312 participants | Moderate |
Mild clobetasol propionate cream regimen (10 to 30 g/day) vs standard clobetasol propionate cream regimen (40 g/day) Mortality at 1 year · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 1 [0.75, 1.32] | 1 study · 312 participants | Low |
Mild clobetasol propionate cream regimen (10 to 30 g/day) vs standard clobetasol propionate cream regimen (40 g/day) Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Mild clobetasol propionate cream regimen (10 to 30 g/day) vs standard clobetasol propionate cream regimen (40 g/day) Adverse events at 1 year · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.94 [0.78, 1.14] | 1 study · 309 participants | Low |
Doxycycline vs prednisolone Disease control at 6 weeks (unadjusted raw data) · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | RR 0.81 [0.72, 0.92] | 1 study · 213 participants | High |
Neoadjuvant treatment vs no neoadjuvant treatment Overall survival (OS), measured by the number of deaths over time Median · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | HR 0.43 [0.15, 1.21] | 2 studies · 171 participants | Very low |
Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment Quality of Life ‐ not measured · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment Overall survival (OS), measured by the number of deaths over time, · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | HR 0.49 [0.15, 1.64] | 1 study · 150 participants | Very low |
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment Adverse Events, · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | RR 2.84 [0.96, 8.37] | 1 study · 142 participants | Very low |
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment Overall response rate (ORR), · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | 1 study · 76 participants | Very low |
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment Time to recurrence (TTR), measured by the number of disease recurrence events over time, · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | HR 0.75 [0.31, 1.79] | 1 study · 150 participants | Very low |
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment Quality of Life ‐ not measured · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Overall survival (OS) · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Adverse events, · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | RR 1 [0.75, 1.34] | 1 study · 20 participants | Low |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Overall response rate (ORR), · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | 1 study · 10 participants | Low |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Time to recurrence ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant treatment vs no neoadjuvant treatment Adverse events, · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | RR 1.58 | 2 studies · 162 participants | Very low |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Quality of life ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) Overall survival (OS), measured by number of deaths over timeMedian · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | 1 study · 23 participants | Moderate |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) Adverse events, · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | RR 8.73 [1.29, 59] | 1 study · 23 participants | Very low |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) Overall response rate (ORR), · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | RR 2.91 [1.02, 8.27] | 1 study · 23 participants | Very low |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) Time to recurrence (TTR), measured by the number of disease recurrence events over time, · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | 1 study · 23 participants | Low |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) Quality of life ‐ not measured · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Overall survival (OS) · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Adverse events, · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | 1 study · 86 participants | Low |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Overall response rate (ORR), · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | RR 1.42 [0.87, 2.32] | 1 study · 86 participants | Low |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Time to response ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant treatment vs no neoadjuvant treatment Overall response rate (ORR), · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Quality of life ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Overall survival (OS) · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Adverse events · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |